US FTC’s Section 13(b) powers must be restored to tackle anticompetitive drug pricing practices, senators told
The Federal Trade Commission must act to combat anticompetitive drug pricing practices by pharmacy benefit managers, US senators were told today. Congress also must pass laws that restore the agency’s powers...To view the full article, register now.
Already a subscriber? Click here to view full article